Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
AssigneeAbbott Laboratories
InventorsDimitri Semizarov, Xin Lu, Ke Zhang, Rick R. Lesniewski
Life of this patent
Estimating the term…
Abstract
The invention is directed to methods and kits that allow for classification of non-small cell lung carcinoma tumors and cell lines according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.
Claims23
A method for obtaining a database of non-small cell lung carcinoma genomic subgroups, the method comprising the steps of:
- (a) obtaining a plurality of m samples comprising at least one NSCLC cell, wherein the samples comprise cell lines or tumors;
- (b) acquiring a data set comprising copy number alteration information from at least one locus from each chromosome from each sample obtained in step (a);
- (c) identifying in the data set samples contaminated by normal cells and eliminating the contaminated samples from the data set, wherein the identifying and eliminating comprises:
- (1) applying a machine learning algorithm tuned to parameters that represent the differences between tumor and normal samples to the data;
- (2) assigning a probability score for normal cell contamination to each sample as determined by the machine learning algorithm;
- (3) eliminating data from the data set for each sample scoring 50% or greater probability of containing normal cells;
- (d) estimating a number of subgroups, r, in the data set by applying an unsupervised clustering algorithm using Pearson linear dissimilarity algorithm to the data set;
- (e) assigning each sample in the data set to at least one cluster using a modified genomic Non-negative Matrix Factorization (gNMF) algorithm, wherein the modified gNMF algorithm comprises:
- (1) calculating divergence of the algorithm after every 100 steps of multiplicative updating using formula (11):
- D
- (
- V
-
-
- WH
- )
- =
- ∑
- i
- =
- 1
- n
-
- ∑
- j
- =
- 1
- m
-
- (
- V
- ij
-
- log
-
-
- V
- ij
- (
- WH
- )
- ij
- -
- V
- ij
- +
- (
- WH
- )
- ij
- )
- (
- 11
- )
- wherein the Vij is the ith row and jth column of matrix V, (WH)ij is the ith row and jth column of matrix (W*H), i runs from 1 to n and n is the number of segments in the data set, and j runs from 1 to m and m is the number of samples in the data set;
- (2) stopping the algorithm if the divergence calculated in step (e)(1) does not decrease by more than about 0.001% when compared to the divergence calculated for the previous 100 steps of multiplicative updating of the algorithm;
- (3) randomly repeating the algorithm for a selected number of runs and calculating a Pearson correlation coefficient matrix of H for the each of run the algorithm using formula (12):
- C
- i
- ,
- j
- =
- ρ
-
- (
- H
- ,
- i
- ,
- H
- ,
- j
- )
- =
- 1
- r
- -
- 1
-
- ∑
- k
-
- (
- H
- k
- ,
- i
- -
- H
- ,
- i
- _
- )
-
- (
- H
- k
- ,
- j
- -
- H
- ,
- j
- _
- )
- s
- H
- ,
- i
-
- s
- H
- ,
- j
- (
- 12
- )
- wherein C is the correlation matrix, Ci,j is the ith row and jth column in the matrix C, H,i and H,j are the ith and jth column vector in matrix H, ρ(H,i, H,j) is the Pearson correlation coefficient between H,i and H,j, i and j run from 1 to m and m is the number of samples in the data set, k runs from 1 to r and r is the number of subgroups from step (d);
- (4) averaging the Pearson correlation coefficient matrices for each run of the algorithm obtained from step (e)(3) to arrive at an average correlation matrix;
- (5) assigning samples into r subgroups by applying a unsupervised clustering algorithm using 1 minus the average correlation matrix determined in step (e)(4) and cutting the dendrogram into r clusters;
- (f) applying a Cophenetic correlation, Bayesian Information Criterion, or a combination thereof to provide a final number of clusters from the data set, wherein each final cluster defines a genomic subgroup for each tumor or cell line sample;
- and
- (g) optionally evaluating the stability of the final number of clusters selected in step (f) using a ten-fold stability test.
A method of classifying a NSCLC tumor or cell line, comprising:
- (a) providing a database, developed through a method comprising:
- (i) obtaining a plurality of m samples comprising at least one NSCLC tumor or cell line;
- (ii) acquiring a first data set comprising copy number alteration information from at least one locus from each chromosome from each sample obtained in step (i);
- (iii) identifying in the first data set samples contaminated by normal cells and eliminating the contaminated samples from the first data set, wherein the identifying and eliminating comprises:
- (1) applying a machine learning algorithm tuned to parameters that represent the differences between tumor and normal samples to the data;
- (2) assigning a probability score for normal cell contamination to each sample as determined by the machine learning algorithm;
- (3) eliminating data from the first data set for each sample scoring 50% or greater probability of containing normal cells;
- (iv) estimating a number of subgroups, r, in the data set by applying an unsupervised clustering algorithm using Pearson linear dissimilarity algorithm to the data set;
- (v) assigning each sample in the data set to at least one cluster using a modified genomic Non-negative Matrix Factorization (gNMF) algorithm, wherein the modified gNMF algorithm comprises:
- (1) calculating divergence of the algorithm after every 100 steps of multiplicative updating using formula (11):
- D
- (
- V
-
-
- WH
- )
- =
- ∑
- i
- =
- 1
- n
-
- ∑
- j
- =
- 1
- m
-
- (
- V
- ij
-
- log
-
-
- V
- ij
- (
- WH
- )
- ij
- -
- V
- ij
- +
- (
- WH
- )
- ij
- )
- (
- 11
- )
- wherein the Vij is the ith row and jth column of matrix V, (WH)ij is the ith row and jth column of matrix (W*H), i runs from 1 to n and n is the number of segments in the data set, and j runs from 1 to m and m is the number of samples in the data set;
- (2) stopping the algorithm if the divergence calculated in step (v)(1) does not decrease by more than about 0.001% when compared to the divergence calculated for the previous 100 steps of multiplicative updating of the algorithm;
- (3) randomly repeating the algorithm for a selected number of runs and calculating a Pearson correlation coefficient matrix of H for each of run the algorithm using formula (12):
- C
- i
- ,
- j
- =
- ρ
-
- (
- H
- ,
- i
- ,
- H
- ,
- j
- )
- =
- 1
- r
- -
- 1
-
- ∑
- k
-
- (
- H
- k
- ,
- i
- -
- H
- ,
- i
- _
- )
-
- (
- H
- k
- ,
- j
- -
- H
- ,
- j
- _
- )
- s
- H
- ,
- i
-
- s
- H
- ,
- j
- (
- 12
- )
- wherein C is the correlation matrix, Ci,j is the ith row and jth column in the matrix C, H,i and H,j are the ith and jth column vector in matrix H, ρ(H,i, H,j) is the Pearson correlation coefficient between H,i and H,j, i and j run from 1 to m and m is the number of samples in the data set, k runs from 1 to r and r is the number of subgroups from step (iv);
- (4) averaging the Pearson correlation coefficient matrices for each run of the algorithm obtained from step (v)(3) to arrive at an average correlation matrix;
- (5) assigning tumors and cell lines in the data set into r subgroups by applying a unsupervised clustering algorithm using 1 minus the average correlation matrix determined in step (v)(4) and cutting the dendrogram into r clusters;
- (vi) applying a Cophenetic correlation, Bayesian Information Criterion, or a combination thereof to provide a final number of clusters from the data set, wherein each final cluster defines a genomic subgroup for each sample;
- and
- (vii) optionally evaluating the stability of the final number of clusters selected in step (vi) using a ten-fold stability test;
- (b) providing a sample suspected of containing NSCLC cells,
- (c) acquiring a second data set, Vsample, comprising copy number alteration information from the same at least one locus from step (ii);
- and
- (d) classifying the sample from Vsample, by comparing Vsample to the clusters determined in steps (i)-(vii).
A method of classifying a therapeutic intervention for arresting or killing non-small cell lung carcinoma (NSCLC) cells, comprising:
- (a) from a panel of NSCLC cells classified according to genomic subgroups, selecting at least one NSCLS cell line from each subgroup, wherein the panel is assembled from a method comprising:
- (i) obtaining a plurality of m samples comprising at least one NSCLC tumor or cell line;
- (ii) acquiring a first data set comprising copy number alteration information from at least one locus from each chromosome from each sample obtained in step (i);
- (iii) identifying in the first data set samples contaminated by normal cells and eliminating the contaminated samples from the first data set, wherein the identifying and eliminating comprises:
- (1) applying a machine learning algorithm tuned to parameters that represent the differences between tumor and normal samples to the data;
- (2) assigning a probability score for normal cell contamination to each sample as determined by the machine learning algorithm;
- (3) eliminating data from the first data set for each sample scoring 50% or greater probability of containing normal cells;
- (iv) estimating a number of subgroups, r, in the data set by applying an unsupervised clustering algorithm using Pearson linear dissimilarity algorithm to the data set;
- (v) assigning each sample in the data set to at least one cluster using a modified genomic Non-negative Matrix Factorization (gNMF) algorithm, wherein the modified gNMF algorithm comprises:
- (1) calculating divergence of the algorithm after every 100 steps of multiplicative updating using formula (11):
- D
- (
- V
-
-
- WH
- )
- =
- ∑
- i
- =
- 1
- n
-
- ∑
- j
- =
- 1
- m
-
- (
- V
- ij
-
- log
-
-
- V
- ij
- (
- WH
- )
- ij
- -
- V
- ij
- +
- (
- WH
- )
- ij
- )
- (
- 11
- )
- wherein the Vij is the ith row and jth column of matrix V, (WH)ij is the ith row and jth column of matrix (W*H), i runs from 1 to n and n is the number of segments in the data set, and j runs from 1 to m and m is the number of samples in the data set;
- (2) stopping the algorithm if the divergence calculated in step (v)(1) does not decrease by more than about 0.001% when compared to the divergence calculated for the previous 100 steps of multiplicative updating of the algorithm;
- (3) randomly repeating the algorithm for a selected number of runs and calculating a Pearson correlation coefficient matrix of H for each of run the algorithm using formula (12):
- C
- i
- ,
- j
- =
- ρ
-
- (
- H
- ,
- i
- ,
- H
- ,
- j
- )
- =
- 1
- r
- -
- 1
-
- ∑
- k
-
- (
- H
- k
- ,
- i
- -
- H
- ,
- i
- _
- )
-
- (
- H
- k
- ,
- j
- -
- H
- ,
- j
- _
- )
- s
- H
- ,
- i
-
- s
- H
- ,
- j
- (
- 12
- )
- wherein C is the correlation matrix, Ci,j is the ith row and jth column in the matrix C, H,i and H,j are the ith and jth column vector in matrix H, ρ(H,i, H,j) is the Pearson correlation coefficient between H,i and H,j, i and j run from 1 to m and m is the number of samples in the data set, k runs from 1 to r and r is the number of subgroups from step (iv);
- (4) averaging the Pearson correlation coefficient matrices for each run of the algorithm obtained from step (v)(3) to arrive at an average correlation matrix;
- (5) assigning tumors and cell lines in the data set into r subgroups by applying a unsupervised clustering algorithm using 1 minus the average correlation matrix determined in step (v)(4) and cutting the dendrogram into r clusters;
- (vi) applying a Cophenetic correlation, Bayesian Information Criterion, or a combination thereof to provide a final number of clusters from the data set, wherein each final cluster defines a genomic subgroup for each sample;
- and
- (vii) optionally evaluating the stability of the final number of clusters selected in step (vi) using a ten-fold stability test
- (viii) selecting at least one NSCLC cell from each cluster selected in step (vi) and assembling into panels defined according to genomic subgroups.
- (b) contacting the at least one NSCLC cell from each subgroup with the therapeutic intervention;
- (c) assaying the effectiveness of the therapeutic intervention to arrest or kill the at least one NSCLC cell from each subgroup;
- (d) classifying the therapeutic intervention according to the determined effectiveness of the therapeutic intervention to arrest or kill the at least one NSCLC cell from each subgroup,
- wherein arresting or killing the at least one NSCLC cell from one subgroup, but not another indicates specificity of the therapeutic intervention to arrest or kill NSCLC cells of that subgroup.
A method of assembling a probe panel for classifying a NSCLC cell from a sample, comprising:
- (a) assembling a database, comprising:
- (i) obtaining a plurality of m samples comprising at least one NSCLC tumor or cell line;
- (ii) acquiring a first data set comprising copy number alteration information from at least one locus from each chromosome from each sample obtained in step (i);
- (iii) identifying in the first data set samples contaminated by normal cells and eliminating the contaminated samples from the first data set, wherein the identifying and eliminating comprises:
- (1) applying a machine learning algorithm tuned to parameters that represent the differences between tumor and normal samples to the data;
- (2) assigning a probability score for normal cell contamination to each sample as determined by the machine learning algorithm;
- (3) eliminating data from the first data set for each sample scoring 50% or greater probability of containing normal cells;
- (iv) estimating a number of subgroups, r, in the data set by applying an unsupervised clustering algorithm using Pearson linear dissimilarity algorithm to the data set;
- (v) assigning each sample in the data set to at least one cluster using a modified genomic Non-negative Matrix Factorization (gNMF) algorithm, wherein the modified gNMF algorithm comprises:
- (1) calculating divergence of the algorithm after every 100 steps of multiplicative updating using formula (11):
- D
-
- (
- V
- ||
- WH
- )
- =
- ∑
- i
- =
- 1
- n
-
- ∑
- j
- =
- 1
- m
-
- (
- V
- ij
-
- log
-
-
- V
- ij
- (
- WH
- )
- ij
- -
- V
- ij
- +
- (
- WH
- )
- ij
- )
- (
- 11
- )
- wherein the Vij is the ith row and jth column of matrix V, (WH)ij is the ith row and jth column of matrix (W*H), i runs from 1 to n and n is the number of segments in the data set, and j runs from 1 to m and m is the number of samples in the data set;
- (2) stopping the algorithm if the divergence calculated in step (v)(1) does not decrease by more than about 0.001% when compared to the divergence calculated for the previous 100 steps of multiplicative updating of the algorithm;
- (3) randomly repeating the algorithm for a selected number of runs and calculating a Pearson correlation coefficient matrix of H for each of run the algorithm using formula (12):
- C
- i
- ,
- j
- =
- ρ
-
- (
- H
- ,
- i
- ,
- H
- ,
- j
- )
- =
- 1
- r
- -
- 1
-
- ∑
- k
-
- (
- H
- k
- ,
- i
- -
- H
- ,
- i
- _
- )
-
- (
- H
- k
- ,
- j
- -
- H
- ,
- j
- _
- )
- s
- H
- ,
- i
-
- s
- H
- ,
- j
- (
- 12
- )
- wherein C is the correlation matrix, Ci,j is the ith row and jth column in the matrix C, H,i and H,j are the ith and jth column vector in matrix H, ρ(H,i, H,j) is the Pearson correlation coefficient between H,i and H,j, i and j run from 1 to m and m is the number of samples in the data set, k runs from 1 to r and r is the number of subgroups from step (iv);
- (4) averaging the Pearson correlation coefficient matrices for each run of the algorithm obtained from step (v)(3) to arrive at an average correlation matrix;
- (5) assigning tumors and cell lines in the data set into r subgroups by applying a unsupervised clustering algorithm using 1 minus the average correlation matrix determined in step (v)(4) and cutting the dendrogram into r clusters;
- (vi) applying a Cophenetic correlation, Bayesian Information Criterion, or a combination thereof to provide a final number of clusters from the data set, wherein each final cluster defines a genomic subgroup for each sample;
- and
- (vii) optionally evaluating the stability of the final number of clusters selected in step (vi) using a ten-fold stability test
- (viii) selecting at least one sample from each cluster selected in step (vi) and assembling into panels defined according to genomic subgroups;
- (b) analyzing the database of step (a) to determine characteristic copy number abnormalities for each subgroup;
- (c) designing a plurality of probes based on the determined characteristic copy number abnormalities for each subgroup and assigning each probe to a genomic subgroup.
A kit for classifying a NSCLC tumor sample or a cell line, comprising:
- (a) instructions to assemble a database, comprising instructions for:
- (i) obtaining a plurality of m samples comprising at least one NSCLC tumor or cell line;
- (ii) acquiring a first data set comprising copy number alteration information from at least one locus from each chromosome from each sample obtained in step (i);
- (iii) identifying in the first data set samples contaminated by normal cells and eliminating the contaminated samples from the first data set, wherein the identifying and eliminating comprises:
- (1) applying a machine learning algorithm tuned to parameters that represent the differences between tumor and normal samples to the data;
- (2) assigning a probability score for normal cell contamination to each sample as determined by the machine learning algorithm;
- (3) eliminating data from the first data set for each sample scoring 50% or greater probability of containing normal cells;
- (iv) estimating a number of subgroups, r, in the data set by applying an unsupervised clustering algorithm using Pearson linear dissimilarity algorithm to the data set;
- (v) assigning each sample in the data set to at least one cluster using a modified genomic Non-negative Matrix Factorization (gNMF) algorithm, wherein the modified gNMF algorithm comprises:
- (1) calculating divergence of the algorithm after every 100 steps of multiplicative updating using formula (11):
- D
-
- (
- V
- ||
- WH
- )
- =
- ∑
- i
- =
- 1
- n
-
- ∑
- j
- =
- 1
- m
-
- (
- V
- ij
-
- log
-
-
- V
- ij
- (
- WH
- )
- ij
- -
- V
- ij
- +
- (
- WH
- )
- ij
- )
- (
- 11
- )
- wherein the Vij is the ith row and jth column of matrix V, (WH)ij is the ith row and jth column of matrix (W*H), i runs from 1 to n and n is the number of segments in the data set, and j runs from 1 to m and m is the number of samples in the data set;
- (2) stopping the algorithm if the divergence calculated in step (v)(1) does not decrease by more than about 0.001% when compared to the divergence calculated for the previous 100 steps of multiplicative updating of the algorithm;
- (3) randomly repeating the algorithm for a selected number of runs and calculating a Pearson correlation coefficient matrix of H for each of run the algorithm using formula (12):
- C
- i
- ,
- j
- =
- ρ
-
- (
- H
- ,
- i
- ,
- H
- ,
- j
- )
- =
- 1
- r
- -
- 1
-
- ∑
- k
-
- (
- H
- k
- ,
- i
- -
- H
- ,
- i
- _
- )
-
- (
- H
- k
- ,
- j
- -
- H
- ,
- j
- _
- )
- s
- H
- ,
- i
-
- s
- H
- ,
- j
- (
- 12
- )
- wherein C is the correlation matrix, Ci,j is the ith row and jth column in the matrix C, Hi, and H,j are the ith and jth column vector in matrix H, ρ(H,i, H,j) is the Pearson correlation coefficient between H,i and H,j, i and j run from 1 to m and m is the number of samples in the data set, k runs from 1 to r and r is the number of subgroups from step (iv);
- (4) averaging the Pearson correlation coefficient matrices for each run of the algorithm obtained from step (v)(3) to arrive at an average correlation matrix;
- (5) assigning tumors and cell lines in the data set into r subgroups by applying a unsupervised clustering algorithm using 1 minus the average correlation matrix determined in step (v)(4) and cutting the dendrogram into r clusters;
- (vi) applying a Cophenetic correlation, Bayesian Information Criterion, or a combination thereof to provide a final number of clusters from the data set, wherein each final cluster defines a genomic subgroup for each sample;
- and
- (vii) optionally evaluating the stability of the final number of clusters selected in step (vi) using a ten-fold stability test;
- and
- (b) optionally, a first, second and third cell line, or isolated genomic DNA thereof, wherein the first cell line is selected from the group consisting of HCC827, NCI-H1437, NCI-H1563, NCI-H1568, NCI-H1623, NCI-H1651, NCI-H1693, NCI-H1755, NCI-H1793, NCI-H1838, NCI-H1944, NCI-H1975, NCI-H1993, NCI-H2023, NCI-H2073, NCI-H2085, NCI-H2087, NCI-H2122, NCI-H2126, NCI-H2228, NCI-H2291, NCI-H23, NCI-H2342, NCI-H2347, NCI-H647, NCI-H920, NCI-H969, CLS-54, LX-289, SK-LU-1, H2882, Calu-6, H358, and H460;
- the second cell line is selected from the group consisting of NCI-H2405, NCI-H522, SK-MES-1, H157, H1819, H2009, H2887, HCC1171, HCC1359, HCC15, HCC193, HCC366, HCC461, HCC515, HCC78, HOP-62, HOP-92, and NCI-H266;
- and
- the third cell line is selected from the group consisting of A549, Calu-3, NCI-H1734, NCI-H838, and HCC95.
Dependencies are inferred from the claim text.